Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: Implications for pharmacological chaperone design for Gaucher disease

Biochemistry

Volumn 50, Issue 49, 2011, Pages 10647-10657

  Orwig, Susan D ^a   Tan, Yun Lei ^b   Grimster, Neil P ^b   Yu, Zhanqian ^b   Powers, Evan T ^b   Kelly, Jeffery W ^b   Lieberman, Raquel L ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; AZASUGARS; ENDOPLASMIC RETICULUM; GAUCHER DISEASE; GLUCOSIDASE; HETEROCYCLES; INTACT CELLS; LOOP CONFORMATION; LYSOSOMAL STORAGE DISORDER; MUTANT ENZYMES; N-LINKED; POINT MUTATIONS; SITE-DIRECTED INHIBITORS; SIX-MEMBERED RINGS; SMALL MOLECULES; THERAPEUTIC STRATEGY; THERMAL DENATURATIONS;

CELL MEMBRANES; CONFORMATIONS; ENZYME ACTIVITY; GENE ENCODING; GENE THERAPY; MICROCOMPUTERS; PYROLYSIS;

ENZYME INHIBITION;

3,4,5,6 TETRAHYDROXYAZEPANE DERIVATIVE; CHAPERONE; GLUCOSYLCERAMIDASE; HETEROCYCLIC COMPOUND; PHARMACOLOGIC CHAPERONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME DENATURATION; GAUCHER DISEASE; HUMAN; HUMAN CELL; IC 50; PH; PRIORITY JOURNAL; PROTEIN CONFORMATION; SYNTHESIS;

AZEPINES; CATALYTIC DOMAIN; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; HYDROGEN-ION CONCENTRATION; MUTATION; PROTEIN DENATURATION;

EID: 82955240553     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi201619z     Document Type: Article

References (76)

1. Beutler, E. and Gelbart, T. (1996) Glucocerebrosidase (Gaucher disease) Hum. Mutat. 8, 207-213 (Pubitemid 26328003)
2. Liou, B., Kazimierczuk, A., Zhang, M., Scott, C. R., Hegde, R. S., and Grabowski, G. A. (2006) Analyses of variant acid β-glucosidases: Effects of Gaucher disease mutations J. Biol. Chem. 281, 4242-4253 (Pubitemid 43847853)
3. Grace, M. E., Newman, K. M., Scheinker, V., Berg-Fussman, A., and Grabowski, G. A. (1994) Analysis of human acid β-glucosidase by site-directed mutagenesis and heterologous expression J. Biol. Chem. 269, 2283-2291 (Pubitemid 24035445)
4. Sawkar, A. R., Schmitz, M., Zimmer, K. P., Reczek, D., Edmunds, T., Balch, W. E., and Kelly, J. W. (2006) Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants ACS Chem. Biol. 1, 235-251
5. Schmitz, M., Alfalah, M., Aerts, J. M., Naim, H. Y., and Zimmer, K. P. (2005) Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease Int. J. Biochem. Cell Biol. 37, 2310-2320 (Pubitemid 41207403)
6. Zimmer, K. P., le Coutre, P., Aerts, H. M., Harzer, K., Fukuda, M., O'Brien, J. S., and Naim, H. Y. (1999) Intracellular transport of acid β-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation) J. Pathol. 188, 407-414 (Pubitemid 29327440)
7. Ron, I. and Horowitz, M. (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity Hum. Mol. Genet. 14, 2387-2398 (Pubitemid 41418000)
8. Bendikov-Bar, I., Ron, I., Filocamo, M., and Horowitz, M. (2011) Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant Blood Cells, Mol., Dis. 46, 4-10
9. Yu, Z., Sawkar, A. R., and Kelly, J. W. (2007) Pharmacologic chaperoning as a strategy to treat Gaucher disease FEBS J. 274, 4944-4950 (Pubitemid 47481193)
10. Cox, T. M. (2010) Gaucher disease: Clinical profile and therapeutic developments Biologics 4, 299-313
11. Lee, L., Abe, A., and Shayman, J. A. (1999) Improved inhibitors of glucosylceramide synthase J. Biol. Chem. 274, 14662-14669
12. Lukina, E., Watman, N., Arreguin, E. A., Banikazemi, M., Dragosky, M., Iastrebner, M., Rosenbaum, H., Phillips, M., Pastores, G. M., Rosenthal, D. I., Kaper, M., Singh, T., Puga, A. C., Bonate, P. L., and Peterschmitt, M. J. (2010) A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1 Blood 116, 893-899
13. Lukina, E., Watman, N., Arreguin, E. A., Dragosky, M., Iastrebner, M., Rosenbaum, H., Phillips, M., Pastores, G. M., Kamath, R. S., Rosenthal, D. I., Kaper, M., Singh, T., Puga, A. C., and Peterschmitt, M. J. (2010) Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study Blood 116, 4095-4098
14. Wraith, J. E. (2006) Limitations of enzyme replacement therapy: Current and future J. Inherited Metab. Dis. 29, 442-447 (Pubitemid 43880649)
15. Michelakakis, H., Skardoutsou, A., Mathioudakis, J., Moraitou, M., Dimitriou, E., Voudris, C., and Karpathios, T. (2002) Early-onset severe neurological involvement and D409H homozygosity in Gaucher disease: Outcome of enzyme replacement therapy Blood Cells, Mol., Dis. 28, 1-4 (Pubitemid 34408981)
16. Reczek, D., Schwake, M., Schroder, J., Hughes, H., Blanz, J., Jin, X., Brondyk, W., Van Patten, S., Edmunds, T., and Saftig, P. (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidase Cell 131, 770-783 (Pubitemid 350087202)
17. Butters, T. D., van den Broek, L. A. G. M., Fleet, G. W. J., Krulle, T. M., Wormald, M. R., Dwek, R. A., and Platt, F. M. (2000) Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis Tetrahedron: Asymmetry 11, 113-124 (Pubitemid 30116779)
18. Mellor, H. R., Neville, D. C., Harvey, D. J., Platt, F. M., Dwek, R. A., and Butters, T. D. (2004) Cellular effects of deoxynojirimycin analogues: Inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides Biochem. J. 381, 867-875 (Pubitemid 39120498)
19. Landon, M. R., Lieberman, R. L., Hoang, Q. Q., Ju, S., Caaveiro, J. M., Orwig, S. D., Kozakov, D., Brenke, R., Chuang, G. Y., Beglov, D., Vajda, S., Petsko, G. A., and Ringe, D. (2009) Detection of ligand binding hot spots on protein surfaces via fragment-based methods: Application to DJ-1 and glucocerebrosidase J. Comput.-Aided Mol. Des. 23, 491-500
20. Zheng, W., Padia, J., Urban, D. J., Jadhav, A., Goker-Alpan, O., Simeonov, A., Goldin, E., Auld, D., LaMarca, M. E., Inglese, J., Austin, C. P., and Sidransky, E. (2007) Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease Proc. Natl. Acad. Sci. U.S.A. 104, 13192-13197 (Pubitemid 351737615)
21. Alfonso, P., Pampin, S., Estrada, J., Rodriguez-Rey, J. C., Giraldo, P., Sancho, J., and Pocovi, M. (2005) Miglustat (NB-DNJ) works as a chaperone for mutated acid β-glucosidase in cells transfected with several Gaucher disease mutations Blood Cells, Mol., Dis. 35, 268-276 (Pubitemid 41267059)
22. Sawkar, A. R., Cheng, W. C., Beutler, E., Wong, C. H., Balch, W. E., and Kelly, J. W. (2002) Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease Proc. Natl. Acad. Sci. U.S.A. 99, 15428-15433 (Pubitemid 35403951)
23. Chang, H. H., Asano, N., Ishii, S., Ichikawa, Y., and Fan, J. Q. (2006) Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients FEBS J. 273, 4082-4092 (Pubitemid 44253660)
24. Sawkar, A. R., D'Haeze, W., and Kelly, J. W. (2006) Therapeutic strategies to ameliorate lysosomal storage disorders: A focus on Gaucher disease Cell. Mol. Life Sci. 63, 1179-1192 (Pubitemid 43939004)
25. Brumshtein, B., Aguilar-Moncayo, M., Garcia-Moreno, M. I., Ortiz Mellet, C., Garcia Fernandez, J. M., Silman, I., Shaaltiel, Y., Aviezer, D., Sussman, J. L., and Futerman, A. H. (2009) 6-Amino-6-deoxy-5,6-di-N-(N′- octyliminomethylidene)nojirimycin: Synthesis, biological evaluation, and crystal structure in complex with acid β-glucosidase ChemBioChem 10, 1480-1485
26. Luan, Z., Higaki, K., Aguilar-Moncayo, M., Ninomiya, H., Ohno, K., Garcia-Moreno, M. I., Ortiz Mellet, C., Garcia Fernandez, J. M., and Suzuki, Y. (2009) Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin ChemBioChem 10, 2780-2792
27. Aguilar-Moncayo, M., Garcia-Moreno, M. I., Trapero, A., Egido-Gabas, M., Llebaria, A., Fernandez, J. M., and Mellet, C. O. (2011) Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: Effect of structural modifications in their pharmacological chaperone potential towards β-glucocerebrosidase Org. Biomol. Chem. 9, 3698-3713
28. Brumshtein, B., Aguilar-Moncayo, M., Benito, J. M., Garcia Fernandez, J. M., Silman, I., Shaaltiel, Y., Aviezer, D., Sussman, J. L., Futerman, A. H., and Ortiz Mellet, C. (2011) Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues Org. Biomol. Chem. 9, 4160-4167
29. Oulaidi, F., Front-Deschamps, S., Gallienne, E., Lesellier, E., Ikeda, K., Asano, N., Compain, P., and Martin, O. R. (2011) Second-generation iminoxylitol-based pharmacological chaperones for the treatment of Gaucher disease ChemMedChem 6, 353-361
30. Wang, G. N., Reinkensmeier, G., Zhang, S. W., Zhou, J., Zhang, L. R., Zhang, L. H., Butters, T. D., and Ye, X. S. (2009) Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease J. Med. Chem. 52, 3146-3149
31. Yu, Z., Sawkar, A. R., Whalen, L. J., Wong, C. H., and Kelly, J. W. (2007) Isofagomine- and 2,5-anhydro-2,5-imino- d -glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention J. Med. Chem. 50, 94-100 (Pubitemid 46105502)
32. Lei, K., Ninomiya, H., Suzuki, M., Inoue, T., Sawa, M., Iida, M., Ida, H., Eto, Y., Ogawa, S., Ohno, K., and Suzuki, Y. (2007) Enzyme enhancement activity of N-octyl-β-valienamine on β-glucosidase mutants associated with Gaucher disease Biochim. Biophys. Acta 1772, 587-596 (Pubitemid 46589985)
33. Lin, H., Sugimoto, Y., Ohsaki, Y., Ninomiya, H., Oka, A., Taniguchi, M., Ida, H., Eto, Y., Ogawa, S., Matsuzaki, Y., Sawa, M., Inoue, T., Higaki, K., Nanba, E., Ohno, K., and Suzuki, Y. (2004) N-Octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: A potential chemical chaperone therapy for Gaucher disease Biochim. Biophys. Acta 1689, 219-228 (Pubitemid 38981599)
34. Sanchez-Olle, G., Duque, J., Egido-Gabas, M., Casas, J., Lluch, M., Chabas, A., Grinberg, D., and Vilageliu, L. (2009) Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease Blood Cells, Mol., Dis. 42, 159-166
35. Diaz, L., Casas, J., Bujons, J., Llebaria, A., and Delgado, A. (2011) New glucocerebrosidase inhibitors by exploration of chemical diversity of N-substituted aminocyclitols using click chemistry and in situ screening J. Med. Chem. 54, 2069-2079
36. Trapero, A., Alfonso, I., Butters, T. D., and Llebaria, A. (2011) Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells J. Am. Chem. Soc. 133, 5474-5484
37. Maegawa, G. H., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G. J., Hamuro, Y., Clarke, J. T., and Mahuran, D. J. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease J. Biol. Chem. 284, 23502-23516
38. Marugan, J. J., Zheng, W., Motabar, O., Southall, N., Goldin, E., Westbroek, W., Stubblefield, B. K., Sidransky, E., Aungst, R. A., Lea, W. A., Simeonov, A., Leister, W., and Austin, C. P. (2011) Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity J. Med. Chem. 54, 1033-1058
39. Lieberman, R. L., Wustman, B. A., Huertas, P., Powe, A. C., Jr., Pine, C. W., Khanna, R., Schlossmacher, M. G., Ringe, D., and Petsko, G. A. (2007) Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease Nat. Chem. Biol. 3, 101-107 (Pubitemid 46134996)
40. Khanna, R., Benjamin, E. R., Pellegrino, L., Schilling, A., Rigat, B. A., Soska, R., Nafar, H., Ranes, B. E., Feng, J., Lun, Y., Powe, A. C., Palling, D. J., Wustman, B. A., Schiffmann, R., Mahuran, D. J., Lockhart, D. J., and Valenzano, K. J. (2010) The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β-glucosidase FEBS J. 277, 1618-1638
41. Steet, R. A., Chung, S., Wustman, B., Powe, A., Do, H., and Kornfeld, S. A. (2006) The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms Proc. Natl. Acad. Sci. U.S.A. 103, 13813-13818 (Pubitemid 44413990)
42. http://www.amicustherapeutics.com/clinicaltrials.
43. Sun, Y., Ran, H., Liou, B., Quinn, B., Zamzow, M., Zhang, W., Bielawski, J., Kitatani, K., Setchell, K. D., Hannun, Y. A., and Grabowski, G. A. (2011) Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse PLoS One 6, e19037
44. Paulsen, H. and Todt, K. (1967) On monosaccharides with nitrogen-yielding seven membered rings Chem. Ber. 100, 512-520
45. Painter, G. F., Eldridge, P. J., and Falshaw, A. (2004) Syntheses of tetrahydroxyazepanes from chiro-inositols and their evaluation as glycosidase inhibitors Bioorg. Med. Chem. 12, 225-232 (Pubitemid 38096234)
46. Qian, X., Moris-Varas, F., Fitzgerald, M. C., and Wong, C. H. (1996) C2-symmetrical tetrahydroxyazepanes as inhibitors of glycosidases and HIV/FIV proteases Bioorg. Med. Chem. 4, 2055-2069 (Pubitemid 27060220)
47. Moris-Varas, F., Qian, X., and Wong, C. H. (1996) Enzymatic/chemical synthesis and biological evaluation of seven-membered iminocyclitols J. Am. Chem. Soc. 118, 7647-7652 (Pubitemid 26285113)
48. Markad, S. D., Karanjule, N. S., Sharma, T., Sabharwal, S. G., and Dhavale, D. D. (2006) Polyhydroxylated homoazepanes and 1-deoxy-homonojirimycin analogues: Synthesis and glycosidase inhibition study Org. Biomol. Chem. 4, 3675-3680 (Pubitemid 44439889)
49. Li, H., Bleriot, Y., Chantereau, C., Mallet, J. M., Sollogoub, M., Zhang, Y., Rodriguez-Garcia, E., Vogel, P., Jimenez-Barbero, J., and Sinay, P. (2004) The first synthesis of substituted azepanes mimicking monosaccharides: A new class of potent glycosidase inhibitors Org. Biomol. Chem. 2, 1492-1499
50. Shih, T. L., Liang, M. T., Wu, K. D., and Lin, C. H. (2011) Synthesis of polyhydroxy 7- and N-alkyl-azepanes as potent glycosidase inhibitors Carbohydr. Res. 346, 183-190
51. Li, H., Liu, T., Zhang, Y., Favre, S., Bello, C., Vogel, P., Butters, T. D., Oikonomakos, N. G., Marrot, J., and Bleriot, Y. (2008) New synthetic seven-membered 1-azasugars displaying potent inhibition towards glycosidases and glucosylceramide transferase ChemBioChem 9, 253-260 (Pubitemid 351196793)
52. Butters, T. D., Alonzi, D. S., Kukushkin, N. V., Ren, Y., and Bleriot, Y. (2009) Novel mannosidase inhibitors probe glycoprotein degradation pathways in cells Glycoconjugate J. 26, 1109-1116
53. Marcelo, F., He, Y., Yuzwa, S. A., Nieto, L., Jimenez-Barbero, J., Sollogoub, M., Vocadlo, D. J., Davies, G. D., and Bleriot, Y. (2009) Molecular basis for inhibition of GH84 glycoside hydrolases by substituted azepanes: Conformational flexibility enables probing of substrate distortion J. Am. Chem. Soc. 131, 5390-5392
54. Xiao, X. and Bai, D. (2001) An efficient and selective method for hydrolysis of acedonides Synlett 4, 535-537 (Pubitemid 32295562)
55. Lohray, B. B., Jayamma, Y., and Chatterjee, M. (1995) Unprecedented selectivity in the reaction of 1,2:5,6-dianhydro-3,4-O-isopropylidenehexitols with benzylamine: A practical synthesis of 3,4,5,6-tetrahydroxyazepanes J. Org. Chem. 60, 5958-5960
56. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72, 248-254
57. Orwig, S. D. and Lieberman, R. L. (2011) Biophysical characterization of the olfactomedin domain of myocilin, an extracellular matrix protein implicated in inherited forms of glaucoma PLoS One 6, e16347
58. Otwinowski, Z. and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276, 307-326 (Pubitemid 27085611)
59. Collaborative Computational Project Number 4 (1994) The CCP4 Suite: Programs for Protein Crystallography Acta Crystallogr. D50, 760
60. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot Acta Crystallogr. D66, 486-501
61. Schuttelkopf, A. W. and van Aalten, D. M. (2004) PRODRG: A tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. D60, 1355-1363 (Pubitemid 41079731)
62. DeLano, W. L. (2002) The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA.
63. Sawkar, A. R., Adamski-Werner, S. L., Cheng, W. C., Wong, C. H., Beutler, E., Zimmer, K. P., and Kelly, J. W. (2005) Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles Chem. Biol. 12, 1235-1244 (Pubitemid 41628259)
64. Gloster, T. M. and Davies, G. J. (2010) Glycosidase inhibition: Assessing mimicry of the transition state Org. Biomol. Chem. 8, 305-320
65. Aguilar-Moncayo, M., Gloster, T. M., Turkenburg, J. P., Garcia-Moreno, M. I., Ortiz Mellet, C., Davies, G. J., and Garcia Fernandez, J. M. (2009) Glycosidase inhibition by ring-modified castanospermine analogues: Tackling enzyme selectivity by inhibitor tailoring Org. Biomol. Chem. 7, 2738-2747
66. Strasberg, P. M. and Lowden, J. A. (1982) The assay of glucocerebrosidase activity using the natural substrate Clin. Chim. Acta 118, 9-20 (Pubitemid 12247066)
67. Yu, L., Ikeda, K., Kato, A., Adachi, I., Godin, G., Compain, P., Martin, O., and Asano, N. (2006) α-1-C-Octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease Bioorg. Med. Chem. 14, 7736-7744 (Pubitemid 44584721)
68. Lieberman, R. L., D'aquino, J. A., Ringe, D., and Petsko, G. A. (2009) The effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability Biochemistry 48, 4816-4827
69. Lieberman, R. L. A guided tour of the structural biology of Gaucher disease: Acid-β-glucosidase and saposin C. Enzyme Res. 2011, in press.
70. Brumshtein, B., Greenblatt, H. M., Butters, T. D., Shaaltiel, Y., Aviezer, D., Silman, I., Futerman, A. H., and Sussman, J. L. (2007) Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid β-glucosidase: Insights into the mechanism of chemical chaperone action in Gaucher disease J. Biol. Chem. 282, 29052-29058 (Pubitemid 47606022)
71. Dvir, H., Harel, M., McCarthy, A. A., Toker, L., Silman, I., Futerman, A. H., and Sussman, J. L. (2003) X-ray structure of human acid-β-glucosidase, the defective enzyme in Gaucher disease EMBO Rep. 4, 704-709 (Pubitemid 36974756)
72. Miao, S., McCarter, J. D., Grace, M. E., Grabowski, G. A., Aebersold, R., and Withers, S. G. (1994) Identification of Glu340 as the active-site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry J. Biol. Chem. 269, 10975-10978
73. Premkumar, L., Sawkar, A. R., Boldin-Adamsky, S., Toker, L., Silman, I., Kelly, J. W., Futerman, A. H., and Sussman, J. L. (2005) X-ray structure of human acid-β-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease J. Biol. Chem. 280, 23815-23819 (Pubitemid 40884867)
74. Wei, R. R., Hughes, H., Boucher, S., Bird, J. J., Guziewicz, N., Van Patten, S. M., Qiu, H., Pan, C. Q., and Edmunds, T. (2011) X-ray and biochemical analysis of N370S mutant human acid β-glucosidase J. Biol. Chem. 286, 299-308
75. Leinekugel, P., Michel, S., Conzelmann, E., and Sandhoff, K. (1992) Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease Hum. Genet. 88, 513-523
76. Desnick, R. J. and Fan, J. Q. (2006) Pharmacologic chaperone therapy for lysosomal diseases. In Gaucher Disease (Futerman, A. H. and Zimran, A., Eds.) pp 377-397, CRC Press, Boca Raton, FL.